Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28857172 | 0.83 | IDO1 (0.38) | MCHR1 | |
| SCHEMBL6238419 | 0.82 | JAK2 (0.33) | — | |
| SCHEMBL745185 | 0.81 | GPR3 (0.36) | — | |
| SCHEMBL2238013 | 0.80 | — | — | |
| SCHEMBL2008537 | 0.79 | KCNH2 (0.32) | — | |
| SCHEMBL8217123 | 0.77 | KMT2A (0.33) | — | |
| SCHEMBL3653763 | 0.76 | — | — | |
| SCHEMBL5484565 | 0.76 | USP2 (0.37) | — | |
| SCHEMBL5487961 | 0.76 | — | — | |
| SCHEMBL348920 | 0.75 | ALDH1A1 (0.48) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | claimed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | claimed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | MCHR1 699/4885EPHX2 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.